Involvement of cysteinyl leukotriene receptor 1 in Aβ1-42-induced neurotoxicity invitro and invivo

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 590-599

  Tang, Su Su ^a   Hong, Hao ^a   Chen, Lan ^a   Mei, Zhen lin ^a   Ji, Miao jin ^a   Xiang, Guo qing ^a   Li, Ning ^a   Ji, Hui ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

A 1 42; Bcl 2; Caspase 3; Cysteinyl leukotriene receptor 1; Memory; Neurotoxicity; NF B

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CASPASE 3; CYSTEINYL LEUKOTRIENE RECEPTOR 1; DONEPEZIL; LEUKOTRIENE RECEPTOR; MEMANTINE; PRANLUKAST; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BRAIN CORTEX; CELL VIABILITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; LYMPHOMA CELL; MALE; MEMORY DISORDER; MOUSE; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION;

AΒ(1-42); BCL-2; CASPASE-3; CYSTEINYL LEUKOTRIENE RECEPTOR 1; MEMORY; NEUROTOXICITY; NF-ΚB;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CASPASE 3; CELLS, CULTURED; CEREBRAL CORTEX; CHROMONES; GENE EXPRESSION; HIPPOCAMPUS; LEUKOTRIENE ANTAGONISTS; MALE; MEMORY; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEURONS; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, LEUKOTRIENE; UP-REGULATION;

EID: 84889580759     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.09.036     Document Type: Article

References (50)

1. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
2. Awasthi A., Matsunaga Y., Yamada T. Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid beta-derived short peptides. Exp. Neurol. 2005, 196:282-289.
3. Boissier E.F., Hunot S., Faucheux B., Duyckaerts C., Hauw J.J., Agid Y., Hirsch E.C. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 1997, 8:2849-2852.
4. Chu J., Praticò D. 5-Lipoxygenase as an endogenous modulator of amyloid β formation invivo. Ann. Neurol. 2011, 69:34-46.
5. Chu J., Praticò D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase. Am. J. Pathol. 2011, 178:1762-1769.
6. Chu J., Praticò D. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J.Neuroinflamm. 2012, 14:127-136.
7. 1 receptors and mitogen-activated protein kinase pathway. Eur. J. Neurosci. 2004, 20:1514-1524.
8. Cissé M., Halabisky B., Harris J., Devidze N., Dubal D.B., Sun B., Orr A., Lotz G., Kim D.H., Hamto P., Ho K., Yu G.Q., Mucke L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011, 469:47-52.
9. Culmsee C., Landshamer S. Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr. Alzheimer Res. 2006, 3:269-283.
10. Daniela L.K., Norbert M. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int. J. Alzheimers Dis. 2010, 10:4061-4069.
11. De Strooper B., Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J.Cell Sci. 2000, 113:1857-1870.
12. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J.Neurosci. 2006, 26:6011-6018.
13. Dinq Q., Fang S.H., Zhou Y., Zhang L.H., Zhang W.P., Chen Z., Wei E.Q. Cysteinyl leukotriene receptor 1 partially mediates brain cryoinjury in mice. Acta Pharmacol. Sin. 2007, 28:945-952.
14. Ferrer I., Marti E., Lopez E., Tortosa A. NF-κB immunoreactivity is observed in association with beta A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol. Appl. Neurobiol. 1998, 24:271-277.
15. Firuzi O., Zhuo J., Chinnici C.M., Wisniewski T., Praticò D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J. 2008, 22:1169-1178.
16. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
17. Giunta B., Fernandez F., Nikolic W.V., Obregon D., Rrapo E., Town T., Tan J. Inflammaging as a prodrome to Alzheimer's disease. J.Neuroinflamm. 2008, 5:1-15.
18. Gorelick P.B. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann. N Y Acad. Sci. 2010, 1207:155-162.
19. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A 1986, 83:4913-4917.
20. Guo J.T., Yu J., Grass D., de Beer F.C., Kindy M.S. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J.Neurosci. 2002, 22:5900-5909.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
22. Huang X.J., Zhang W.P., Li C.T., Shi W.Z., Fang S.H., Lu Y.B., Chen Z., Wei E.Q. Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation. Glia 2008, 56:27-37.
23. Jimenez S., Baqlietto-Varqas D., Caballero C., Moreno-Gonzalez I., Torres M., Sanchez-Varo R., Ruano D., Vizuete M., Gutierrez A., Vitorica J. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J.Neurosci. 2008, 28:11650-11661.
24. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 1997, 94:2642-2647.
25. Kawano T., Matsuse H., Kondo Y., Machida I., Saeki S., Tomari S., Mitsuta K., Obase Y., Fukushima C., Shimoda T., Kohno S. Cysteinyl leukotrienes induce nuclear factor-κB activation and RANTES production in a murine model of asthma. J.Allergy Clin. Immunol. 2003, 112:369-374.
26. Laevis, Tropicials X. Environment, Housing, and Management, in: National Research Council, eighth ed. The National Academic Press, Washington, D. C. 1996, 80-103.
27. Manev H., Chen H., Dzitoyeva S., Manev R. Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:315-319.
28. O'Hare E., Scopes D.I., Treherne J.M., Monaghan J., Palmer P.M., Amijee H., Kim E.M. Novel anti-inflammatory compound SEN1176 alleviates behavioral deficits induced following bilateral intrahippocampal injection of aggregated amyloid-β1-42. J.Alzheimers Dis. 2011, 25:219-229.
29. Palop J.J., Mucke L. Amyloid-β induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
30. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2003, Academic Press, San Diego, CA. second ed.
31. Rohn T.T., Vyas V., Hernandez-Estrada T., Nichol K.E., Christie L.A., Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J.Neurosci. 2008, 28:3051-3059.
32. Russo I., Caracciolo L., Tweedie D., Choi S.H., Greig N.H., Barlati S., Bosetti F. 3,6'-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J.Neurochem. 2012, 122:1181-1192.
33. Selkoe D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J.Clin. Invest. 2002, 11:1375-1381.
34. Serhan C.N., Haeggström J.Z., Leslie C.C. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 1996, 10:1147-1158.
35. Singh R.K., Gupta S., Dastidar S., Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010, 85:336-349.
36. Stadelmann C., Deckwerth T.L., Srunivasan A., Bancher C., Bruck W., Jellinger K., Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease: evidence for apoptotic cell death. Am. J. Pathol. 1999, 155:1459-1466.
37. Suzuki S., Takeuchi K., Ishinaga H., Basbaum C., Majima Y. Leukotriene D4 upregulates MUC2 gene transcription in human epithelial cells. Pharmacology 2008, 81:221-228.
38. 1R-mediated amyloid-β generation in mice. Neuropharmacology 2013, 65:182-192.
39. Terai K., Matsuo A., McGeer P.L. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 1996, 735:159-168.
40. Thal D.R., Rüb U., Orantes M., Braak H. Phases of Aβ deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
41. Thompson C., Cloutier A., Boss Y., Thivierge M., Gouill C.L., Larivée P., McDonald P.P., Stankova J., Rola-Pleszczynski M. CysLT1 receptor engagement induces activator protein-1- and NF-kappaB-dependent IL-8 expression. Am. J. Respir. Cell Mol. Biol. 2006, 35:697-704.
42. Valerio A., Boroni F., Benarese M., Sarnico I., Ghisi V., Bresciani L.G., Ferrario M., Borsani G., Spano P., Pizzi M. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur. J. Neurosci. 2006, 23:1711-1720.
43. Wang L., Du C., Lv J., Wei W., Cui Y., Xie X. Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. J.Immunol. 2011, 187:2336-2345.
44. 1R-mediated NF-κB pathways in primary neurons. Neurochem. Int. 2013, 62:340-347.
45. Wang C., Yang X.M., Zhuo Y.Y., Zhou H., Lin H.B., Cheng Y.F., Xu J.P., Zhang H.T. The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int. J. Neuropsychopharmacol. 2012, 9:1-18.
46. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
47. Yang J., Hu Z.L., Jiang B., Ni L., Jin Y., Chen J.G., Wang F. Effect of chloramine-T on long-term potentiation at synapses between perforant path and dentate gyrus in hippocampus of rats invivo. Neurotoxicology 2011, 32:199-205.
48. Zhang W.P., Hu H., Zhang L., Dinq W., Yao H.T., Chen K.D., Sheng W.W., Chen Z., Wei E.Q. Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci. Lett. 2004, 363:247-251.
49. Zhang Y.J., Zhang L., Ye Y.L., Fang S.H., Zhou Y., Zhang W.P., Lu Y.B., Wei E.Q. Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice. Acta Pharmacol. Sin. 2006, 27:1553-1560.
50. Zotova E., Nicoll J.A., Kalaria R., Holmes C., Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res. Ther. 2010, 2:1-9.